Cognitive Behavior vs Bright Light Therapy for Insomnia in Women Undergoing Chemotherapy for Breast Cancer: A - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Comparative Effectiveness of Cognitive Behavioral Therapy and Bright Light Treatment for Insomnia in Women with Breast Cancer Undergoing Chemotherapy

  • By

  • Trang Thuy Do

  • Jordan Maccora

  • Rebecca Wallace

  • Veronica Aedo-Lopez

  • Marliese Alexander

  • Sonia Ancoli-Israel

  • Bei Bei

  • Robert Blum

  • Frances Boyle

  • Daphne Day

  • Justine Diggens

  • Prudence A. Francis

  • Maria Ftanou

  • Sheila N. Garland

  • Alysia Kepert

  • Duncan Mortimer

  • Andrew J. K. Phillips

  • Sharad Sharma

  • Lesley Stafford

  • Michelle White

  • Joshua F. Wiley

  • August 27, 2026

Share

  • 1

    Insomnia affects 62% and moderate to severe fatigue affects 43% of women with breast cancer undergoing chemotherapy.

  • 2

    Cognitive behavior therapy for insomnia (CBT-I) is the first-line treatment for insomnia, including among cancer patients.

  • 3

    Bright light therapy (BLT) aims to improve sleep and reduce fatigue by targeting circadian rhythms during chemotherapy.

  • 4

    The study examines the efficacy of CBT-I and BLT for insomnia and fatigue in women with breast cancer receiving chemotherapy.

  • 5

    Participants were randomly assigned to CBT-I, BLT, combined CBT-I and BLT, or sleep hygiene education in a factorial trial design.

Original Source(s)

Cognitive Behavior vs Bright Light Therapy for Insomnia in Women Undergoing Chemotherapy for Breast Cancer: A

  • by Trang Thuy Do, Jordan Maccora, Rebecca Wallace, Veronica Aedo-Lopez, Marliese Alexander, Sonia Ancoli-Israel, Bei Bei, Robert Blum, Frances Boyle, Daphne Day, Justine Diggens, Prudence A. Francis, Maria Ftanou, Sheila N. Garland, Alysia Kepert, Duncan Mortimer, Andrew J. K. Phillips, Sharad Sharma, Lesley Stafford, Michelle White, Joshua F. Wiley

  • August 27, 2026

Related Content

Error in the Byline

  • August 27, 2026

FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer Following Landmark Clinical Trial Led by Dana-Farber

he U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

  • by

  • August 26, 2026

  • 5 min
Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas